# OH2 Injection in Melanoma

Source: https://onco.cc/trials/nct05868707/  
OnCo record `nct05868707` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of OH2 in melanoma, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.

## Summary

OH2 Injection in Melanoma is a phase 3 interventional study registered as NCT05868707 by Binhui Biopharmaceutical Co., Ltd., with 340 participants planned, started 2023-03-08 and due to reach its primary completion in 2026-03. Interventions recorded: OH2 and Salvage chemotherapy or best supportive care.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05868707
- Phase: 3
- Setting: To Evaluate a Phase III Study of OH2 Versus Investigator-selected Salvage Chemotherapy or Best Supportive Care in Melanoma Patients Who Had Failed Standard Therapy
- Sponsor: Binhui Biopharmaceutical Co., Ltd.
- Enrolled: 340

## Sources

- ClinicalTrials.gov NCT05868707: https://clinicaltrials.gov/study/NCT05868707

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- companies: [Binhui Biopharmaceutical](https://onco.cc/companies/binhui-biopharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct05868707.json